Results from a cohort study suggest that vision loss, a common side effect after plaque radiotherapy for uveal melanoma, may be mitigated or avoided entirely thanks to prophylactic…
The constantly evolving science and emerging study results focused on adjuvant therapies have drastically changed the treatment landscape for patients with melanoma. Along with targeted therapies, immunotherapies have…
After prior case studies showed promising results with PD-1 inhibition followed by chemotherapy, a group of doctors, led by Georgia Sofia Karachaliou, MD, MSc, of the Department of Medicine…
A new analysis published in European Urology suggests that the risk window of recurrence for surgically treated renal cell carcinoma (RCC) may be longer than previously thought. Hoping…
Published final results of the DeCOG-SLT trial add evidence that patients who have a positive sentinel lymph-node biopsy, and have immediate complete lymph node dissection, do not achieve…
A preliminary clinical study looking at previously untreated metastatic melanoma showed promising results when treating with the combination of an IL-2 signaling agonist and nivolumab. Primary trial objectives…
Benjamin Prince, MD, MSCI, FAAAAI, allergist/immunologist at Nationwide Children’s Hospital in Columbus, Ohio, discusses primary immunodeficiency diseases. Many patients have a genetic defect that results in part of…
Despite an abundance of preclinical evidence supporting the treatment strategy of combining an IDO1 inhibitor with anti-PD-1/PD-L1 immunotherapy, the results of a recent clinical trial were unable to confirm…
In this video, Dr. Daniel George, MD, discusses the results of a sunitinib study that helped change the treatment landscape for renal cell carcinoma (RCC). Compared to placebo,…
Results from the CARMENA trial, presented at the 2019 annual meeting of the American Society of Clinical Oncology suggest that cytoreductive nephrectomy should no longer be considered the…
